Vyriad – http://www.vyriad.com/
Overview
We are a privately-held clinical stage biotechnology company based in Rochester, Minnesota. We are dedicated to the development and commercialization of a new generation of targeted oncolytic virus based cancer therapies.
We have assembled and obtained exclusive rights to a portfolio of intellectual property relating to viruses that are designed to trigger oncolysis, or the destruction of cancer cells. These viruses are also designed to stimulate a patient’s own immune system to fight the cancer at the same time. Our two leading oncolytic virus product candidates, which are derived respectively from measles and vesicular stomatitis virus (commonly known as VSV) have shown promising anti-tumor activity in early stage clinical trials in an academic setting, which prompted us to license them into the company.
We were incorporated under Delaware law in May 2012 under the name Omnis International Co. In December 2015, we acquired Magnis Therapeutics, LLC, a Minnesota limited liability company, in a merger transaction pursuant to which we merged a newly-formed and wholly-owned subsidiary of our company with and into Magnis, with Magnis surviving as our wholly-owned subsidiary. In May 2016, we merged Magnis into our company and changed our name to Vyriad, Inc.
Vyriad PPM.PDF – available for review by contacting: avivalev-ari@alum.berkeley.edu
2012pharmaceutical
sjwilliamspa